Arrowstreet Capital
REGN icon

Arrowstreet Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Arrowstreet Capital’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$133M Sell
171,571
-23,124
-12% -$17.7M 0.07% 262
2025
Q4 		$150M Buy
194,695
+2,111
+1% +$1.43M 0.09% 228
2025
Q3 		$108M Buy
192,584
+186,521
+3,076% +$105M 0.07% 268
2025
Q2 		$3.18M Buy
+6,063
New +$3.38M ﹤0.01% 1314
2023
Q4 		– Sell
-2,262
Closed -$1.86M – 1536
2023
Q3 		$1.86M Hold
2,262
– – ﹤0.01% 873
2023
Q2 		$1.63M Buy
+2,262
New +$1.74M ﹤0.01% 883
2023
Q1 		– Sell
-1,661
Closed -$1.2M – 1488
2022
Q4 		$1.2M Buy
1,661
+656
+65% +$484K ﹤0.01% 987
2022
Q3 		$692K Sell
1,005
-177,537
-99% -$112M ﹤0.01% 1052
2022
Q2 		$106M Buy
178,542
+142,319
+393% +$92.5M 0.15% 147
2022
Q1 		$25.3M Buy
36,223
+31,609
+685% +$20M 0.03% 366
2021
Q4 		$2.91M Buy
+4,614
New +$2.84M ﹤0.01% 938
2021
Q1 		– Sell
-700
Closed -$338K – 2479
2020
Q4 		$338K Sell
700
-11,500
-94% -$6.21M ﹤0.01% 2098
2020
Q3 		$6.83M Buy
+12,200
New +$7.4M 0.01% 1005
2019
Q3 		– Sell
-403,526
Closed -$126M – 1684
2019
Q2 		$126M Buy
403,526
+93,195
+30% +$31M 0.28% 87
2019
Q1 		$127M Buy
310,331
+233,356
+303% +$96.1M 0.3% 62
2018
Q4 		$28.8M Buy
+76,975
New +$28.2M 0.08% 245
2018
Q1 		– Sell
-1,000
Closed -$376K – 1301
2017
Q4 		$376K Buy
+1,000
New +$405K ﹤0.01% 1106
2015
Q4 		– Sell
-40,069
Closed -$18.6M – 1567
2015
Q3 		$18.6M Sell
40,069
-31,336
-44% -$16.8M 0.09% 219
2015
Q2 		$36.4M Buy
+71,405
New +$34.8M 0.21% 119
2014
Q1 		– Sell
-31,466
Closed -$8.66M – 1303
2013
Q4 		$8.66M Buy
+31,466
New +$9.05M 0.05% 318

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Arrowstreet Capital's REGN Position: Q1 2026 in Review

Arrowstreet Capital reduced its Regeneron Pharmaceuticals (REGN) stake by 12% in Q1 2026, selling an estimated $17.7M and leaving 171,571 shares worth $133M. The position accounts for 0.07% of the portfolio, ranked #262.

Arrowstreet Capital first reported a position in REGN in Q4 2013 and has held it in 20 quarters since. The position peaked at $150M in Q4 2025. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Arrowstreet Capital held 171,571 shares of Regeneron Pharmaceuticals worth $133M as of Q1 2026.
  • Arrowstreet Capital sold 23,124 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $17.7M.
  • Regeneron Pharmaceuticals made up 0.07% of Arrowstreet Capital's portfolio in Q1 2026, its #262 holding.
  • Arrowstreet Capital first reported a position in Regeneron Pharmaceuticals in Q4 2013 and has held it in 20 quarters since.
  • Arrowstreet Capital's Regeneron Pharmaceuticals position peaked at $150M in Q4 2025.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Arrowstreet Capital's 13F filing for Q1 2026, filed 14 May 2026.